A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

NCT01080612 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: 330 mg pregabalin controlled release
DRUG: 330 mg pregabalin controlled release
DRUG: 330 mg pregabalin controlled release
DRUG: 300 mg pregabalin immediate release

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.